OPG Polyclonal Antibody, PerCP Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-20624R-PerCP |
| Product Name | OPG Polyclonal Antibody, PerCP Conjugated |
| Applications |
WB
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Human, Mouse, Rat |
| Predicted Reactivity | Dog, Rabbit |
| Specifications | |
| Conjugation | PerCP |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human OPG |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 367 |
| Swiss Prot | O00300 |
| Subcellular location | Secreted |
| Synonyms | Tumor necrosis factor receptor superfamily member 11B; TNFRSF11B; Osteoclastogenesis inhibitory factor; Osteoprotegerin; OCIF; OPG |
| Background | Acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |